$181 Million is the total value of Abingworth LLP's 13 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RNA | Prosensa | $34,860,000 | +20.4% | 6,213,924 | 0.0% | 19.23% | -11.9% | |
| SUPN | Supernus | $32,148,000 | +18.6% | 3,600,000 | 0.0% | 17.74% | -13.2% | |
| PTLA | Portola | $32,140,000 | +0.6% | 1,240,912 | 0.0% | 17.73% | -26.4% | |
| AMRN | Amarinspons adr | $14,638,000 | -7.7% | 8,087,486 | 0.0% | 8.08% | -32.4% | |
| CEMP | Cempra | $8,243,000 | -6.9% | 714,285 | 0.0% | 4.55% | -31.8% | |
| OGXI | Oncogenex Pharma | $7,088,000 | +40.8% | 603,740 | 0.0% | 3.91% | +3.1% | |
| ZGNX | Zogenix | $6,632,000 | -17.2% | 2,335,218 | 0.0% | 3.66% | -39.4% | |
| GWPH | GW Pharma (US)spons adr | $6,067,000 | +42.8% | 102,200 | 0.0% | 3.35% | +4.6% | |
| HPTX | Hyperion | $1,612,000 | +28.0% | 62,500 | 0.0% | 0.89% | -6.3% | |
| ANTH | Anthera | $1,467,000 | +9.5% | 437,994 | 0.0% | 0.81% | -19.9% | |
| ZLCS | Zalicus | $96,000 | +10.3% | 78,966 | 0.0% | 0.05% | -19.7% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Abingworth Management LTD #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-21
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-NT | 2024-08-09 |
| 13F-NT | 2024-05-03 |
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.